SCHEMBL612957

SCHEMBL612957

CC(C)[C@H](O[Si](C)(C)C)c1cccc(Br)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.40
TDO2 P48775 1/20 0.40
MBTD1 Q05BQ5 1/20 0.35
L3MBTL3 Q96JM7 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 1/20 0.35
KRAS P01116 1/20 0.35
SOS1 Q07889 1/20 0.35
GABRA1 P14867 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
PARP1 P09874 1/20 0.34
CYP3A4 P08684 3/20 0.33
CYP2D6 P10635 3/20 0.33
SLC6A2 P23975 3/20 0.33
SLC6A4 P31645 3/20 0.33
SLC6A3 Q01959 3/20 0.33
KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27836347 0.87 IDO1 (0.38) IDO1TDO2MBTD1L3MBTL3ALDH1A1
SCHEMBL13779026 0.87 IDO1 (0.38) IDO1TDO2MBTD1L3MBTL3ALDH1A1
SCHEMBL613438 0.83 KCNA5 (0.36) IDO1TDO2ALDH1A1PARP1CYP3A4
SCHEMBL2754728 0.83 KCNA5 (0.36) IDO1TDO2ALDH1A1PARP1CYP3A4
SCHEMBL16203056 0.82 ALDH1A1 (0.42) IDO1TDO2ALDH1A1CTSA
SCHEMBL18706770 0.80 IDO1 (0.43) IDO1TDO2MBTD1L3MBTL3ALDH1A1
SCHEMBL1525071 0.78 IDO1 (0.39) IDO1TDO2MBTD1L3MBTL3ALDH1A1
SCHEMBL18706984 0.76 IDO1 (0.40) IDO1TDO2MBTD1L3MBTL3ALDH1A1
SCHEMBL8851108 0.76 IDO1 (0.60) IDO1TDO2ALDH1A1MAPK1SLC6A2
SCHEMBL3413604 0.75 SLC6A2 (0.39) IDO1TDO2ALDH1A1MAPK1GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8450527-B2 Amine derivative compounds for treating ophthalmic diseases and disorders ACUCELA INC. (US) 2013-05-28 US disclosed
US-20120041038-A1 AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS ACUCELA INC. (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041038-A1 AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS PDE6D, CLN6, AADAT IDO1 505/4885TDO2 823/4885MBTD1 157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.